SynaptixBio_BACKGROUND_dark2.png

New biotech firm launched to develop ‘revolutionary’ treatment for one of world’s rarest diseases

A new biotech business SynaptixBio has been launched to tackle one of the world’s rarest neurodegenerative diseases.


SynaptixBio is working to develop the world’s first disease-modifying treatment for TUBB4a leukodystrophy, including H-ABC - a debilitating and potentially life-limiting condition.


To continue reading please go to the article on Uganda ScieGirl






43 views0 comments

Recent Posts

See All

Dr Dan Williams, CEO and Co-Founder of new biotech business SynaptixBio, discusses how the search is on to find the first treatment for one of the world’s rarest diseases, TUBB4A-associated leukodystr

SynaptixBio, an Oxford, UK-based research company, has been launched by a worldwide team of medical and pharmaceutical scientists to develop the world’s first disease modifying treatment for leukodyst